2025 is anticipated to be a pivotal year for FDA oncology drug approvals, with numerous groundbreaking therapies expected to transform cancer care. Among these, several treatments hold promise for revolutionizing care in breast cancer, lung cancer, and multiple myeloma – three of the most economically burdensome cancers globally.

Download our e-book, authored by Laura Bobolts, PharmD, BCOP, SVP Clinical Strategy and Growth, to explore the top five drugs poised to make a significant impact this year and why they could change the oncology landscape.